NEW YORK (GenomeWeb News) – Agilent Technologies and Applied Proteomics today announced a collaboration to develop multiplex protein assays and workflow solutions for multiple reaction monitoring (MRM) using mass spectrometry.

Applied Proteomics will use Agilent instruments, including the 6490 Triple Quadrupole MS/MS, 1290 Infinity LC, RapidFire 360 MS system, and Bravo liquid handling technologies to "optimize the throughput of highly multiplexed proteomic assays," the firms said.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.